Independent opinions of independent directors on the provision for asset impairment in 2021
In accordance with the Listing Rules of Shenzhen Stock Exchange, the governance standards of listed companies, the guidance on the establishment of independent director system in listed companies, the articles of association, the independent director system and other relevant regulations and systems, as independent directors of Berry Genomics Co.Ltd(000710) (hereinafter referred to as “the company”), we hereby express the following independent opinions on the provision for asset impairment of the company in 2021:
The provision for asset impairment this time complies with the accounting standards and relevant regulations of the company, the actual situation of the company’s assets, and the approval procedures for the provision for asset impairment are legal and compliant. After the provision for asset impairment is made, the 2021 annual financial statements can more fairly reflect the company’s annual financial status, asset value and operating results as of December 31, 2021, which is conducive to providing investors with more authentic and reliable accounting information, and there is no damage to the interests of the company and shareholders, especially minority shareholders.
We agree with the proposal on the provision for asset impairment in 2021 deliberated and adopted at the 16th meeting of the ninth board of directors. The voting procedure of the board of directors is open and transparent, and the deliberation procedure is in line with the relevant provisions of laws, regulations and the articles of association.
Independent directors: Wang Xiuping, Li Guangchao, Wang Sijia April 14, 2022
